Jul. 29 at 1:02 PM
$IBRX There's been a lot of talk about
$JNJ 's Inlexio taking mkt sare from Anktiva, BS! The only thing slowing down sales of anktiva is freaking
$MRK slow walking their BCG supply increase .
JNJ captured 33% of the market with
$30 million in sales, then the current addressable financial market size for this specific commercial layer is currently sitting around
$90 million to
$100 million per quarter.
If IBRX successfully prints a
$51 million quarter next week, the market share breakdown shifts drastically. Anktiva would single-handedly command 51% to 56% of the total revenue generated in this therapeutic market.
The reason Anktiva can claim a higher revenue percentage than JNJ while potentially serving a similar number of total patients is its premium pricing structure as a novel interleukin-15 superagonist.
The Monopoly Disruptor:
JNJ’s massive corporate size and 75% volume growth, IBRX is still capturing the majority of the actual dollars being spent on BCG-unresponsive bladder cancer
